Searchable abstracts of presentations at key conferences in endocrinology

ea0070ep200 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Remogliflozin reduces gout risk in type 2 diabetes

Mahapatra Hariballav , Khuntia Monalisa , Sahoo Abhay

Background and Aim: SGLT2 inhibitors are relatively new class of medications in the management portfolio of type 2 diabetes (T2DM). Despite their late introduction, they have gained substantial up–gradation in the treatment algorithm as suggested by various international bodies. Remogliflozin is an SGLT2i licensed in India and several other countries for the management of T2DM. We studied the effect of Remogliflozin on serum uric acid (SUA) levels in subjects with type 2...

ea0073pep7.3 | Presented ePosters 7: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Dapagliflozin improves transaminitis in non alcoholic fatty liver disease among adults with type 2 diabetes

Mahapatra Hariballav , Mahapatra Laxminarayan , Khuntia Monalisa , Sahoo Abhay Kumar , Sucharita Soumya

Use of SGLT2 inhibitors are increasing worldwide due to its potential antihyperglycemic role. Additionally they have shown to be beneficial in reducing the cardiac and renal complications in diabetes. There are sporadic reports to show their effects on liver enzymes. We did a single centre, open label, prospective trial to evaluate the role of dapagliflozin on hepatic enzymes in diabetic patients with non alcoholic fatty liver disease (NAFLD). Abdominal sonography was used to ...

ea0073aep234 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Vildagliptin is a safe and powerful oral antidiabetic drug for elderly adults with type 2 diabetes

Mahapatra Hariballav , 2 Laxminarayan Mahapatra , Khuntia Monalisa , Sahoo Abhay Kumar , Sucharita Soumya

DPP4 inhibitors are special class of drugs that not only improve metabolism in a glucose dependant manner, but also suppress the glucagon axis. Due to its glucose dependant insulinotropic action, vildagliptin is thought to be relatively safe for people who are at risk of developing low glucose episodes. We studied the glucose lowering potential and hypoglycemic effects of vildagliptin among elderly diabetics who were uncontrolled with at least 2 oral antidiabetic medications. ...

ea0073aep264 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Treatment recommendations for dapagliflozin across a cardio-renal and viscero metabolic (crv-m) continuum: an expert consensus delphi study

Das Ashok , Awasthi Rajeev , Sahay Manisha , Sahoo Abhay , Hazra Prakash , Kapoor Nitin , Tiwaskar Mangesh , Bhandarkar Prashant , Sahay Rakesh , Bhattacharya Saptarshi , Saboo Banshi , Pandit Kaushik , Kishor Kamal , Marwah Tiven , Agrawal Navneet , Sharma Kamal , Khanna Umesh , Bantwal Ganapathi , Joshi Ameya , Kerkar Prafulla , Kalra Sanjay

IntroductionDapagliflozin is sub-optimally utilised in the real world. There is a lack of a comprehensive collaborative guidance for a practical approach to manage patients with cardiometabolic, renometabolic and viscerometabolic disorders. Patients across the CRV-M continuum includes patients with varied clinical profiles.MethodsTwo round Delphi study was conducted using a virtual online-digital connect appr...